BR112013019011A2 - inibição de il17 e ifn-gama para o tratamento de inflamação autoimune - Google Patents

inibição de il17 e ifn-gama para o tratamento de inflamação autoimune

Info

Publication number
BR112013019011A2
BR112013019011A2 BR112013019011A BR112013019011A BR112013019011A2 BR 112013019011 A2 BR112013019011 A2 BR 112013019011A2 BR 112013019011 A BR112013019011 A BR 112013019011A BR 112013019011 A BR112013019011 A BR 112013019011A BR 112013019011 A2 BR112013019011 A2 BR 112013019011A2
Authority
BR
Brazil
Prior art keywords
ifn
treatment
autoimmune inflammation
gamma inhibition
gamma
Prior art date
Application number
BR112013019011A
Other languages
English (en)
Other versions
BR112013019011B1 (pt
Inventor
Chevrier Carine
Leban Johann
Baumgartner Roland
Tasler Stefan
Saeb Wael
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of BR112013019011A2 publication Critical patent/BR112013019011A2/pt
Publication of BR112013019011B1 publication Critical patent/BR112013019011B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

inibição de il17 e ifn-gama para o tratamento de inflamação autoimune a presente invenção refere-se a compostos da fórmula geral (i) e ao sal ou solvato farmaceuticamente aceitável do mesmo como agentes anti-inflamatórios e imunomodulatórios.
BR112013019011-6A 2011-01-28 2012-01-27 Inibidores de il17 e ifn-gama, e seu uso BR112013019011B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161437061P 2011-01-28 2011-01-28
EP11152515 2011-01-28
EP11152515.0 2011-01-28
US61/437,061 2011-01-28
PCT/EP2012/051357 WO2012101261A1 (en) 2011-01-28 2012-01-27 Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation

Publications (2)

Publication Number Publication Date
BR112013019011A2 true BR112013019011A2 (pt) 2017-07-11
BR112013019011B1 BR112013019011B1 (pt) 2021-10-13

Family

ID=46577835

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019011-6A BR112013019011B1 (pt) 2011-01-28 2012-01-27 Inibidores de il17 e ifn-gama, e seu uso

Country Status (23)

Country Link
US (1) US8592456B2 (pt)
EP (1) EP2668182B1 (pt)
JP (1) JP5969505B2 (pt)
KR (1) KR101875248B1 (pt)
CN (1) CN103476771B (pt)
AR (1) AR085040A1 (pt)
AU (1) AU2012210489B2 (pt)
BR (1) BR112013019011B1 (pt)
CA (1) CA2825684C (pt)
DK (1) DK2668182T3 (pt)
EA (1) EA027351B1 (pt)
ES (1) ES2664507T3 (pt)
IL (1) IL227626A0 (pt)
MX (1) MX353762B (pt)
MY (1) MY162397A (pt)
PL (1) PL2668182T3 (pt)
PT (1) PT2668182T (pt)
RU (1) RU2013139663A (pt)
SG (1) SG192176A1 (pt)
TW (1) TWI520955B (pt)
UA (1) UA113160C2 (pt)
UY (1) UY33884A (pt)
WO (1) WO2012101261A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348726B (es) * 2011-01-28 2017-06-26 4Sc Discovery Gmbh Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
EP2738170B1 (en) * 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
SG11201407919WA (en) 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104978732A (zh) * 2014-04-11 2015-10-14 中国船舶工业系统工程研究院 一种摄像机参数标定板
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
CN111433202A (zh) 2017-09-06 2020-07-17 埃慕尼克股份公司 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物
CN110511213B (zh) * 2018-05-22 2021-10-19 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341519A (zh) * 2019-08-09 2021-02-09 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
WO2023281097A1 (en) 2021-07-09 2023-01-12 Immunic Ag Methods for treating cancer
WO2023198873A1 (en) 2022-04-14 2023-10-19 Immunic Ag Deuterated rorgamma/rorgammat inverse agonists
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172985T1 (de) * 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
EP0979226B1 (en) * 1997-04-21 2005-11-09 Sumitomo Pharmaceuticals Company, Limited Isoxazole derivatives
JP3237608B2 (ja) * 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
PL1725544T3 (pl) * 2004-03-09 2009-10-30 Boehringer Ingelheim Pharmaceuticals Inc 3-[4-Heterocyklilo-1,2,3-triazol-1-ilo]-N-arylobenzamidy jako inhibitory wytwarzania cytokin, do leczenia przewlekłych chorób zapalnych
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2009300317A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AR076984A1 (es) * 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
MX348726B (es) * 2011-01-28 2017-06-26 4Sc Discovery Gmbh Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.

Also Published As

Publication number Publication date
RU2013139663A (ru) 2015-03-10
US8592456B2 (en) 2013-11-26
MX353762B (es) 2018-01-26
AU2012210489B2 (en) 2017-01-12
US20120196861A1 (en) 2012-08-02
ES2664507T3 (es) 2018-04-19
PL2668182T3 (pl) 2018-11-30
NZ613592A (en) 2015-03-27
CA2825684A1 (en) 2012-08-02
UA113160C2 (xx) 2016-12-26
EA027351B1 (ru) 2017-07-31
EP2668182A1 (en) 2013-12-04
CA2825684C (en) 2021-11-23
CN103476771B (zh) 2015-12-23
JP2014504608A (ja) 2014-02-24
CN103476771A (zh) 2013-12-25
AU2012210489A1 (en) 2013-08-15
TW201309682A (zh) 2013-03-01
TWI520955B (zh) 2016-02-11
MY162397A (en) 2017-06-15
AR085040A1 (es) 2013-08-07
PT2668182T (pt) 2018-01-31
UY33884A (es) 2012-08-31
BR112013019011B1 (pt) 2021-10-13
SG192176A1 (en) 2013-08-30
EA201300862A1 (ru) 2014-04-30
WO2012101261A1 (en) 2012-08-02
JP5969505B2 (ja) 2016-08-17
MX2013008718A (es) 2014-02-17
DK2668182T3 (da) 2018-01-29
IL227626A0 (en) 2013-09-30
KR20140041440A (ko) 2014-04-04
KR101875248B1 (ko) 2018-08-02
EP2668182B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
BR112013019011A2 (pt) inibição de il17 e ifn-gama para o tratamento de inflamação autoimune
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
UY39630A (es) Inhibidores de bromodominios
AU2012214029A8 (en) Rorgammat inhibitors
BR112015032693A2 (pt) inibidores de bromodomínio
MX2015011273A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
IN2014MN02652A (pt)
CO6940432A2 (es) Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
MX349159B (es) Derivados deuterados de ivacaftor.
IN2014MN00988A (pt)
IN2014MN02657A (pt)
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CR20130045A (es) Compuestos terapéuticos
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
PL2925757T3 (pl) Związki i kompozycje do leczenia chorób pasożytniczych
CR20140134A (es) Composiciones farmacéuticas
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
EA201270728A1 (ru) Пуриновые соединения
EA201591177A1 (ru) Трициклические соединения для ингибирования канала cftr
ES2722926T3 (es) Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2012, OBSERVADAS AS CONDICOES LEGAIS.